Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Biotechnology

Healthcare
$13.78 +1.49%

+$0.37 today

Market cap
$1.22B
Beta
0.56
P/E (TTM)
-13.9
EPS (TTM)
-$1.83
52W Low $12.59High $47.65

Volume 1.39M

Average 1.48M

MLYS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Mineralys Therapeutics, Inc.NASDAQ: MLYS

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $24.66M rose 191.2% year over year, ahead of the +144.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 17.6% from the prior quarter. Over 3 fiscal years it compounded at +94.7% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +62.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$24.66M+17.6% QoQ
Last fiscal yearDec 2025
$38.6M+62.0% YoY
LTMJun 2026
$69.2M+144.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+191.2%-100.0%-291.2 pp
1 year+62.0%-100.0%-162.0 pp
3-year CAGR+94.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
38.6M USD
Year-over-year change
+62.0%
4-year CAGR
+99.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How MLYS compares with its peers on the latest reported figures

  • MLYS's LTM Jun 2026 selling, general & admin of $69.2M is the 3rd highest of the 7 companies compared; the peer median is $33.01M.
  • Its year-over-year change of +144.0% is the 2nd highest of 7, against a peer median of +30.6%.
  • Over three fiscal years its annual growth of +94.7% compares with a peer median of +22.0%.
MLYS Competitors Peer median
Selling, General & Admin for MLYS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$376.47M +23.4%+19.5%57.8%
VERAVera Therapeutics, Inc.LTM Jun 2026$153.89M +144.6%+66.0%—
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$69.2M +144.0%+94.7%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026$39.04M +38.9%+14.7%195.2%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$26.99M +11.1%+24.6%82.5%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$21.4M +37.8%+45.9%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$9.79M +21.7%+16.7%—
Peer median (excluding MLYS) $33.01M+30.6%+22.0%82.5%

Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development16.31M26.25M70.36M168.58M132.01M
Selling, General & Admin2.42M5.23M14.3M23.82M38.6M
Operating Expenses18.73M31.48M84.66M192.4M170.6M
Depreciation & Amortization00043K59K
EBITDA(19.38M)(28.12M)(71.9M)(177.77M)(154.59M)
EBITDA Margin—————
Operating Income(18.73M)(31.48M)(84.66M)(192.4M)(170.6M)
Operating Margin—————
Interest Income01.68M12.76M14.59M15.95M
Interest Expense27K1.68M000
Other Income / Expenses(683K)1.68M12.76M14.59M15.95M
Income Before Tax(19.41M)(29.8M)(71.9M)(177.81M)(154.65M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(19.41M)(29.8M)(71.9M)(177.81M)(154.65M)
Net Margin—————
EPS (Basic)(3.89)(5.77)(1.99)(3.66)(2.29)
EPS (Diluted)(3.89)(5.77)(1.99)(3.66)(2.29)
Weighted Avg Shares4.98M5.17M36.19M48.54M67.66M
Weighted Avg Shares (Diluted)4.98M5.17M36.19M48.54M67.66M

Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Intrinsic Alpha fair value

Locked

Current Price

$13.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.